A recently published study from University of Washington researchers is drawing interest across the region as Southwest Washington communities continue to confront fentanyl-related deaths and strained treatment systems. According to reporting by MyNorthwest, Dr. Lucinda Grande — a clinical associate professor of family medicine at UW — has released new peer‑reviewed findings suggesting that extremely low doses of ketamine may help people transition more safely and more quickly from fentanyl to buprenorphine.

Grande has studied low‑dose ketamine for over a decade. In the research described in the recent paper, clinicians at a 24‑hour crisis center in Alabama used very small doses of ketamine for patients already in moderate withdrawal. According to reporting by MyNorthwest, the technique often reduced withdrawal symptoms within about 30 minutes, allowing patients to begin therapeutic doses of buprenorphine without triggering a more severe withdrawal episode.

Buprenorphine, prescribed under brand names such as Suboxone and Sublocade, is one of two primary medications used to treat opioid use disorder. Grande told the station’s interviewers that the ketamine‑assisted approach could lower a significant barrier to treatment: the fear that starting buprenorphine too soon after fentanyl use will worsen withdrawal.

MyNorthwest reported that Grande emphasized the potential for stability once a patient transitions onto buprenorphine or methadone. She noted in the interview that individuals using illicit fentanyl face continuous overdose risk and spend much of their time trying to avoid withdrawal. Medication‑assisted treatment, she said, can replace that cycle with predictable, regulated dosing and space to rebuild daily life.

The reporting also underscored that misconceptions remain a barrier. Grande addressed the common belief that buprenorphine or methadone simply replace one addiction with another, stating that properly prescribed medications do not create the uncontrolled or harmful use patterns that define addiction.

Despite promising early results, the research is still new, and MyNorthwest reported that many clinicians — including addiction specialists — may not yet be familiar with the ketamine‑assisted technique. Grande said she hopes awareness will increase as more medical professionals learn about the findings.

The study arrives during a period of heightened fentanyl-related harm across Washington State, including in Cowlitz County, where emergency responders and public health agencies continue to report rising overdose deaths. While the new research was conducted outside the region, its focus on barriers to treatment aligns closely with challenges facing local clinics, outreach workers, and families struggling to navigate the transition from illicit fentanyl to evidence‑based medical care.

Further study is needed before the technique becomes part of standard treatment protocols. But according to reporting by MyNorthwest, researchers see cautious optimism in the early outcomes and hope that the low cost and simplicity of the intervention will make it accessible in a variety of clinical settings.

Why this matters for Cowlitz County

Southwest Washington has experienced sharp increases in fentanyl‑related deaths in recent years, and local providers regularly cite difficulty initiating patients onto buprenorphine because of withdrawal‑related fears. If continued research supports Grande’s findings, the technique could offer a new tool for regional clinics, crisis responders, and hospital emergency departments working to stabilize patients and reduce overdose risk.

Sources

MyNorthwest: UW researcher: Low-cost ketamine treatment shows promise in helping fentanyl users seek recovery